Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » AMZB

 - UBBFriend: Email this page to someone!    
Author Topic: AMZB
skip
Member


Icon 1 posted      Profile for skip     Send New Private Message       Edit/Delete Post   Reply With Quote 
News out...

Amazon Biotech Announces Submission to FDA of HIV Test Protocol for AMZ0026 as Add-on to Conventional HAART Therapy in Non-Symptomatic HIV Subjects
May 2, 2006 1:00:00 AM
NEW YORK, NY -- (MARKET WIRE) -- 05/02/06 -- Amazon Biotech, Inc. (OTC BB: AMZB) today announced that it has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immuno-modulating agent in HAART-treated HIV subjects. The current study design includes 32 non-symptomatic HIV subjects who are currently treated with Highly Active Anti-Retroviral Therapy (HAART), whereby 50% of the subjects will be continuing their current HAART regimen without change, and 50% will receive AMZ0026 along with their current HAART regimen. The study will entail six months treatment with monitoring of T Cell increases, HIV plasma viral load decreases and improvements in quality of life.

In discussions with the FDA, Amazon Biotech, Inc. was advised to revise the former Phase II HIV protocol to allow for a smaller patient population, clarification of inclusion and exclusion criteria and more specific safety monitoring procedures.

The drug formulation is based upon the Amazon Biotech, Inc. philosophy of several active ingredients working in combination, utilizing cutting edge whole plant pharmaceutical drug technology to create a natural, healthier pharmaceutical drug. An added benefit to using all natural ingredients is the higher probability of an acceptable safety profile.

Amazon Biotech, Inc. is investing its time and capital into filling the obvious need for an AIDS therapy capable of effectively eradicating HIV virus, improving immunological markers of the disease and providing improved quality of life with minimal adverse side effects to individuals with AIDS when used independently or in concert with conventional HAART therapy.

The revised AMZ0026 HIV protocol is designed to evaluate this breakthrough investigational drug's ability to attain the above-mentioned effects through assessment of AMZ0026's effect on benchmark clinical markers for AIDS and on quality of life when used in unison with HAART therapy, in this six month study.

A parallel placebo-controlled study in the non-symptomatic non-treated HIV population has also been submitted and has been announced in an earlier press release. The placebo-controlled study also plans to enroll 32 subjects (not 60, as previously announced) in subjects infected with HIV-1, but not yet treated with antivirals. T cell levels and HIV viral counts will be monitored.

These protocols are part of an existing IND (Investigational New Drug Application). FDA feedback on these protocols is expected within a few weeks. The Company will provide more details on the FDA's input at a later date.

Approximately 40,000 people are infected with HIV each year in the United States alone and over 3,000,000 people died of AIDS in 2005 (http://www.cdc.gov/hiv/PUBS/Facts/At-A-Glance.htm and UNAIDS).

Submission of a protocol with the FDA does not guarantee that the FDA will approve the protocol, nor does it mean that there won't be changes made in the protocol. Amazon Biotech is working closely with the FDA, hoping to arrive at a protocol that will satisfy first and foremost, all safety concerns and also show efficacy.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes,'' "expects,'' "anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Commitment to do a study does not represent that the Company has FDA approval on the Protocol to start the study, nor that the study design announced will be the final protocol design.

CONTACT:

LC group
Rick Lutz
404-261-1196

Posts: 2741 | From: Seattle | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
Livinonklendathu
Member


Icon 1 posted      Profile for Livinonklendathu     Send New Private Message       Edit/Delete Post   Reply With Quote 
Might be good for a pop off this:


AMZB -- Amazon Biotech, Inc.
Com ($0.001)

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection

NEW YORK, NY, Sep 05, 2006 (MARKET WIRE via COMTEX) -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.

Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.


Contact:
LC Group
Rick Lutz
(404) 261-1196

SOURCE: Amazon Biotech, Inc


Copyright 2006 Market Wire, All rights reserved.

http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5 Ciw%5C2006%5C09%5C05%5C82815748.html%26clientid%3D168%26provider%3DInternet_Wire &symbol=AMZB


Filings:

http://www.pinksheets.com/quote/filings.jsp?symbol=AMZB

--------------------
......in Psychiatry circles it's known as a "warning sign"

Posts: 1736 | From: Saint Louis | Registered: Jul 2005  |  IP: Logged | Report this post to a Moderator
Livinonklendathu
Member


Icon 1 posted      Profile for Livinonklendathu     Send New Private Message       Edit/Delete Post   Reply With Quote 
O/S 37.6 M
Float 33.7 M

--------------------
......in Psychiatry circles it's known as a "warning sign"

Posts: 1736 | From: Saint Louis | Registered: Jul 2005  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Bidding up already.

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
skip
Member


Icon 1 posted      Profile for skip     Send New Private Message       Edit/Delete Post   Reply With Quote 
posted this on the other thread...

some things I like from the last 10Q...

As of June 29, 2006, 37,590,634 shares of our common stock were outstanding.

NOTE E - JOINT VENTURE AGREEMENT

On November 17, 2005, the Company entered into a Letter of Intent to enter into a possible joint venture with Punzi Medical Center ("PMC") in connection with Amazon Biotech, Inc.'s ("Amazon") efforts to obtain from the United States Food and Drug Administration ("FDA") approval of AMZ0026 currently under development by Amazon. Subject to the terms and conditions of the agreement, PMC shall (a) fund all costs and expenses incurred in connection with the clinical trials, (b) make its facilities available for the conduct of the clinical trials, and (c) provide consulting services to Amazon with respect to the conduct of the clinical trials and their approval by the FDA. In consideration for the obligations of PMC, Amazon shall pay to PMC royalties equal to an agreed upon percentage of the net revenues generated by any sales of AMZ0026 during an agreed upon time period following the FDA's final approval.
------
------

that said, there are some things I don't like, such as the dilution that has been going on for a while for employee compensation and general funding activities. They have been losing money, but are in the developmental phase, and have been issuing stock to survive this phase. You'll note though, that much of this stock was issued at much higher prices, like in the upper teens and twenties...

(edit)

http://stockcharts.com/h-sc/ui?s=AMZB&p=D&yr=0&mn=6&dy=0&id=p21672817592

---

gapping up already...

Posts: 2741 | From: Seattle | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Running, I'm in!

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
10of13
Member


Icon 1 posted      Profile for 10of13     Send New Private Message       Edit/Delete Post   Reply With Quote 
Needs more volume to keep it moving...

--------------------
#1 Rule: Protect your capital! #2 Rule: Never fall for the BS on the boards!

Posts: 8890 | Registered: Jan 2006  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
0.15 - up 30%.
Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Give it time for the traders to pick it up.

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
10of13
Member


Icon 1 posted      Profile for 10of13     Send New Private Message       Edit/Delete Post   Reply With Quote 
Getting a few hits...lookin' more positive...needs to break .15

--------------------
#1 Rule: Protect your capital! #2 Rule: Never fall for the BS on the boards!

Posts: 8890 | Registered: Jan 2006  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
1 left at .15

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
repastyouth
Member


Rate Member
Icon 1 posted      Profile for repastyouth     Send New Private Message       Edit/Delete Post   Reply With Quote 
Needs more volume to break that .15 mark.
Posts: 33 | From: Washington | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Give it time!!! News is down on microcaptrader. All those idiots on Ihub haven't seen it.

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
stockmanforlife
Member


Rate Member
Icon 1 posted      Profile for stockmanforlife     Send New Private Message       Edit/Delete Post   Reply With Quote 
AMZB is all BS!!!! The product was part of APPI Advanced Plant Pharmaceuticals. APPI never did anything with the product and neither will AMZB. Don't throw away good money on scam artists who live in Israel. Their proprietary whole plant process is BS as well. I wouldn't take their product if I was sick.....thats for sure!!!!
Posts: 8 | From: new york | Registered: Sep 2006  |  IP: Logged | Report this post to a Moderator
10of13
Member


Icon 1 posted      Profile for 10of13     Send New Private Message       Edit/Delete Post   Reply With Quote 
Stockman...
Deep breath...yah OK?

--------------------
#1 Rule: Protect your capital! #2 Rule: Never fall for the BS on the boards!

Posts: 8890 | Registered: Jan 2006  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Ask now at .16... we may run today.

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share